Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AgfiledCriticalBayer Ag
Priority to DO2002000326ApriorityCriticalpatent/DOP2002000326A/en
Publication of DOP2002000326ApublicationCriticalpatent/DOP2002000326A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere a la utilización del 1,1-dióxido de 2-[4-({[(2R)-8-isopropoxi-croman-2-il]metil} amino)butil] - 1 ,2-benzisotiazol-3 (2H)-ona, de sus sales, hidratos yio solvatos fisiológicamente aceptables, en especial de sus clorhidratos para la preparación de un medicamento para la profilaxis y/o tratamiento de la enfermedad de Parkinson.The present invention relates to the use of 2- [4 - ({[(2R) -8-isopropoxy-chroman-2-yl] methyl} amino) butyl] -1,2-benzisothiazole-1,1-dioxide 3 (2H) -one, of its physiologically acceptable salts, hydrates and solvates, especially its hydrochlorides for the preparation of a medicament for the prophylaxis and / or treatment of Parkinson's disease.
Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-amino)phenyl]-benzamide for the manufacture of pharmaceutical compositions for treatment of gastrointestinal stromal tumors